We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Researchers Complete Re-creation of 1918 Virus

By Biotechdaily staff writers
Posted on 28 Oct 2005
After almost 10 years of research, scientists have completed the re-creation of the influenza virus that took the lives of 20-50 million people worldwide in 1918 and 1919.

The work was conducted by scientists from the U.S. More...
Armed Forces Institute of Pathology (Washington, DC, USA), the U.S. Centers of Disease Control and Prevention (Atlanta, GA, USA), and Mount Sinai School of Medicine (New York, NY, USA). The findings have convinced the scientists that the 1918 virus began as an avian virus.

It has been difficult to study the 1918 virus since samples were not preserved at the time of the pandemic. Dr. Jeffery Taubenberger, chief of pathology at the U.S. Armed Forces Institute of Pathology, and his team have focused on publishing sequences for the genes of the virus, using materials preserved in the Alaskan permafrost and in the lungs of U.S. solders killed by the flu. They recently finished sequencing the three genes remaining. They have discovered 10 changes in amino acids that differ from other avian viruses, which suggest the virus might have mutated on its own to become transmissible in humans. The H5N1 avian virus that has so far claimed the lives of more than 50 people in Asia has already made five of these 10 changes. The team's work was published in the October 6, 2005, issue of Nature.

The other researchers, from Mount Sinai and the CDC, have reconstructed the virus by using reverse genetics, in order to learn what made it so lethal. The virus had the ability to enter cells deep in the lungs that flu viruses usually do not reach. The researchers focused on a gene in the re-created 1918 virus that allowed the virus to attach to cells and multiply. When that gene was removed, the virus lost its virulence. Moreover, certain genetic mutations of the virus have been found in the H5N1 strain, suggesting the new strain may follow a similar route. This team's work was published in the October 7, 2005, issue of Science.

According to Terrence Tumpey, a senior scientist at the CDC, the 1918 virus would be unlikely today to cause a pandemic. It is in the same family as those viruses many people have been exposed to over recent years, either by vaccination or natural infection, and thus they have developed some immune protection.

"This groundbreaking research helps unlock the mystery of the 1918 flu pandemic and is critically important in our efforts to prepare for pandemic influenza,” said CDC director Dr. Julie Gergerding.





Related Links:
Armed Forces Institute of Pathology
CDC
Mount Sinai

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.